Aaron Farberg, MD

Join Dermatology Times’ quarterly editor in chief Aaron Farberg, MD, as he highlights significant advancements in gene expression profile testing for cutaneous melanoma.

Aaron Farberg, MD, explores advancements in melanoma and cSCC prognostic tools, the role of gene expression profiling in inflammatory diseases, and initiatives aimed at supporting early-career dermatologists at Fall Clinical 2024.

Panelists discuss how red light therapy has emerged as a versatile, noninvasive treatment in aesthetic dermatology, offering benefits such as collagen stimulation and skin rejuvenation while comparing favorably with other cosmetic treatments in terms of minimal adverse effects and high patient satisfaction rates.

Panelists discuss how red light therapy accelerates wound healing by stimulating cellular energy production, increasing blood flow, reducing inflammation, and promoting collagen synthesis, leading to faster tissue repair and regeneration in various clinical scenarios.

Aaron Farberg, MD, discusses how red light therapy utilizes specific wavelengths of light to penetrate skin cells, stimulating mitochondrial function, potentially leading to various therapeutic effects such as reduced inflammation and improved tissue repair.

Farberg discusses data recently published in Geriatrics demonstrating low rates of recurrence.

Step therapy can delay appropriate care and potentially worsen patients' conditions, writes Dermatology Times Spring Editor in Chief Aaron Farberg, MD.

Dermatology Times' Spring Editor in Chief, Aaron Farberg, MD, discusses the business strategy known as buy and bill.

Farberg is looking forward to another year of top-notch presentations at Fall Clinical 2023.

Aaron Farberg, MD, and Shanna Miranti, MPAS, PA-C, discuss the upcoming approvals of nivolumab and IDP-126.

John Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.

Jonathan S Zager, MD, FACS, FSSO reviews the clinical trial data relating to the BOLT study examining the use of sonidegib treatment in patients with locally advanced basal cell carcinoma, highlighting the critical differences in study design and data readouts between the BOLT and EVRIANCE trials.

Andrew Weinstein, MD, MPH, FAAD and Jonathan S Zager, MD, FACS, FSSO explore the potential rationale behind observed variations in the and GLI and PTCH expression data within the EVRAINCE trial and comment on potential factors contributing to bias within the study.

Lilia Correa-Selm, MD, FAAD, FACMS, reviews the clinical trial data relating to the EVRIANCE study examining the use of vismodegib treatment in patients with locally advanced basal cell carcinoma, highlighting key efficacy and safety endpoints.

In part 4 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

In part 3 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

In part 2 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

In part 1 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

Experts in dermatology discuss their use cases of cemiplimab and reinforce the need for dermatologists to utilize novel and effective treatments within their patient populations.

Dr Aaron Farberg discusses the role of cemiplimab in the management of BCC; highlighting the need to increase the engagement of a multidisciplinary team in the use of this treatment.

Neal Bhatia, MD, and Aaron Farberg, MD, discuss the progression of basal carcinoma and the evolving treatment approaches to this condition.

In the final part of this Frontline Forum series, Joshua Zeichner, MD, FAAD; Hilary Baldwin, MD; Zoe Diana Draelos, MD; Aaron S. Farberg, MD, FAAD; and Leon H. Kircik, MD, discuss the main pillars of acne and topical treatments available for patients with acne.

In part 3 of this Frontline Forum series, Joshua Zeichner, MD, FAAD; Hilary Baldwin, MD; Zoe Diana Draelos, MD; Aaron S. Farberg, MD, FAAD; and Leon H. Kircik, MD, discuss the main pillars of acne and topical treatments available for patients with acne.

In part 2 of this Frontline Forum series, Joshua Zeichner, MD, FAAD; Hilary Baldwin, MD; Zoe Diana Draelos, MD; Aaron S. Farberg, MD, FAAD; and Leon H. Kircik, MD, discuss the main pillars of acne and topical treatments available for patients with acne.

In part 1 of this Frontline Forum series, Joshua Zeichner, MD, FAAD; Hilary Baldwin, MD; Zoe Diana Draelos, MD; Aaron S. Farberg, MD, FAAD; and Leon H. Kircik, MD, discuss the main pillars of acne and topical treatments available for patients with acne.

An expert in acne management provide his opinion on the differences between generic vs brand acne treatments and shares his thoughts on the utilization of available isotretinoin formulations.

Aaron Farberg, M.D discusses some common acne causes, highlighting the role of stress, diet, and androgen receptors for this condition.

Dr Aaron Farberg shares his recommendations for discussing acne treatment options with patients and provides insight on setting and managing patients’ goals and expectations.